Bharat Biotech’s oral cholera vaccine successful in clinical studies

Study findings have been published in the Science Direct, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single component oral cholera vaccine

Hyderabad: Bharat Biotech’s Oral Cholera Vaccine Hillchol has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.

According to a press release, the study findings have been published in the Science Direct, Vaccine journal 126998 to assess a double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single component oral cholera vaccine Hillchol in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India.

The highlights from the findings included Robust Immunogenicity, Strong Safety Profile and The vaccine was well-tolerated and immunogenic across all age groups — including infants (≥1 year), children, and adults.

“This publication highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,” said Dr Krishna Ella, Executive Chairman of Bharat Biotech.